Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing

被引:9
|
作者
Lopez, Adriana Gamboa [1 ,2 ]
Allu, Srinivasa Rao [3 ,4 ]
Mendez, Patricia [1 ,2 ]
Reddy, Guddeti Chandrashekar [3 ,4 ]
Maul-Newby, Hannah M. [1 ,2 ]
Ghosh, Arun K. [3 ,4 ]
Jurica, Melissa S. [1 ,2 ]
机构
[1] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA
[2] Univ Calif Santa Cruz, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA
[3] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[4] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
D O I
10.1021/acschembio.0c00965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Small molecules that target the spliceosome SF3B complex are potent inhibitors of cancer cell growth. The compounds affect an early stage of spliceosome assembly when U2 snRNP first engages the branch point sequence of an intron. Employing an inactive herboxidiene analog (iHB) as a competitor, we investigated factors that influence inhibitor interactions with SF3B to interfere with pre-mRNA splicing in vitro. Order-of-addition experiments show that inhibitor interactions are long lasting and affected by both temperature and the presence of ATP. Our data are also consistent with the model that not all SF3B conformations observed in structural studies are conducive to productive inhibitor interactions. Notably, SF3B inhibitors do not impact an ATP-dependent rearrangement in U2 snRNP that exposes the branch binding sequence for base pairing. We also report extended structure-activity relationship analysis of the splicing inhibitor herboxidiene. We identified features of the tetrahydropyran ring that mediate its interactions with SF3B and its ability to interfere with splicing. In the context of recent structures of SF3B bound to inhibitor, our results lead us to extend the model for early spliceosome assembly and inhibitor mechanism. We postulate that interactions between a carboxylic acid substituent of herboxidiene and positively charged SF3B1 side chains in the inhibitor binding channel are needed to maintain inhibitor occupancy while counteracting the SF3B transition to a dosed state that is required for stable U2 snRNP interactions with the intron.
引用
收藏
页码:520 / 528
页数:9
相关论文
共 50 条
  • [1] SF3B1 thermostability as an assay for splicing inhibitor interactions
    Amorello, Angela N.
    Reddy, Guddeti Chandrashekar
    Melillo, Bruno
    Cravatt, Benjamin F.
    Ghosh, Arun K.
    Jurica, Melissa S.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2025, 301 (02)
  • [2] SF3B1 Association with Chromatin Determines Splicing Outcomes
    Kfir, Nir
    Lev-Maor, Galit
    Glaich, Ohad
    Alajem, Adi
    Datta, Arnab
    Sze, Siu K.
    Meshorer, Eran
    Ast, Gil
    CELL REPORTS, 2015, 11 (04): : 618 - 629
  • [3] SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
    Furney, Simon J.
    Pedersen, Malin
    Gentien, David
    Dumont, Amaury G.
    Rapinat, Audrey
    Desjardins, Laurence
    Turajlic, Samra
    Piperno-Neumann, Sophie
    de la Grange, Pierre
    Roman-Roman, Sergio
    Stern, Marc-Henri
    Marais, Richard
    CANCER DISCOVERY, 2013, 3 (10) : 1122 - 1129
  • [4] SF3B1: from core splicing factor to oncogenic driver
    Bak-Gordon, Pedro
    Manley, James L.
    RNA, 2025, 31 (03) : 314 - 332
  • [5] Potential role of the splicing factor SF3B1 in epigenetic regulation
    Deliard, Sandra
    Okamoto, Yasuyuki
    Madzo, Jozef
    Jelinek, Jaroslav
    Issa, Jean-Pierre
    CANCER RESEARCH, 2017, 77
  • [6] SF3B1 Splicing Mutation in the Context of Therapy Related MDS
    Volpe, Virginia Olivia
    Al Ali, Najla
    Chan, Onyee
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    BLOOD, 2020, 136
  • [7] U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing
    Choi, Namjeong
    Liu, Yongchao
    Oh, Jagyeong
    Ha, Jiyeon
    Zheng, Xuexiu
    Shen, Haihong
    CELLS, 2020, 9 (12) : 1 - 17
  • [8] Cancer-associated SF3B1 mutations inhibit mRNA nuclear export by disrupting SF3B1-THOC5 interactions
    Liu, Gang
    Zhao, Bo
    Shi, Yueru
    Wan, Youzhong
    JOURNAL OF BIOCHEMISTRY, 2024, 176 (06): : 437 - 448
  • [9] Targeting SF3B1 mediated splicing control in chronic lymphocytic leukemia
    Chen, Rong
    Plunkett, William
    Kipps, Thomas J.
    Wu, Catherine J.
    Keating, Michael
    Chen, Yuling
    Rassenti, Laura
    Gruber, Michaela
    Ghia, Emanuela
    Qi, Yuan
    Su, Xiaoping
    Wong, Jessica
    LEUKEMIA & LYMPHOMA, 2017, 58 : 219 - 219
  • [10] SF3B1 Splicing Mutation in the Context of Therapy-Related MDS
    Volpe, Virginia
    Al Ali, Najla
    Padron, Eric
    Sallman, David
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S320 - S320